ArticleAlzheimer's & dementia (New York, N. Y.)2016
Alzheimer's drug-development pipeline: 2016.
Article in Alzheimer's & dementia (New York, N. Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cognitive training for people with mild to moderate dementia.The Cochrane database of systematic reviews · 2019Pooled it
- Health economic evaluations of non-pharmacological interventions for persons with dementia and their informal caregivers: a systematic review.BMC geriatrics · 2018Pooled it
- Redirecting Alzheimer's disease therapeutics: Multitarget drugs and complementary non-pharmacological strategies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- The global patent landscape of the drugs for treating Alzheimer's disease from 2014-2023.BMC neurology · 2025Article
- Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies.Current medicinal chemistry · 2025Review
- Selective HLA Class II Allele-Restricted Activation of Atabecestat Metabolite-Specific Human T-Cells.Chemical research in toxicology · 2024Article
- Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults.Alzheimer's research & therapy · 2024Article
- Paradigm shift required for translational research on the brain.Experimental & molecular medicine · 2024Review
- The Pathological Effects of Circulating Hydrophobic Bile Acids in Alzheimer's Disease.Journal of Alzheimer's disease reports · 2023Review
- A Review of the Recent Advances in Alzheimer's Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics.Diagnostics (Basel, Switzerland) · 2022Review
- Effects of different kinds of anti-Alzheimer's disease drugs on cognitive improvement: protocol for a systematic review and network meta-analysis of phase III clinical trials.Systematic reviews · 2022Article
- Impact of non-binding FDA guidances on primary endpoint selection in Alzheimer's disease trials.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- Targeted Screening for Alzheimer's Disease Clinical Trials Using Data-Driven Disease Progression Models.Frontiers in artificial intelligence · 2022Article
- Alzheimer's disease drug development pipeline: 2022.Alzheimer's & dementia (New York, N. Y.) · 2022Review
- Alzheimer's Disease: An Update and Insights Into Pathophysiology.Frontiers in aging neuroscience · 2022Review
- Network-based stage-specific drug repurposing for Alzheimer's disease.Computational and structural biotechnology journal · 2022Article
- Quetiapine Combined with Sodium Valproate in Patients with Alzheimer's Disease with Mental and Behavioral Symptoms Efficacy Observation.Journal of healthcare engineering · 2022Article
- New approaches to symptomatic treatments for Alzheimer's disease.Molecular neurodegeneration · 2021Review
- Alzheimer's disease drug development pipeline: 2021.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- Who funds Alzheimer's disease drug development?Alzheimer's & dementia (New York, N. Y.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease (AD) is growing in frequency and new therapies are urgently needed.
methodsWe assessed clinicaltrials.gov (accessed 1-4-2016) to determine the number and characteristics of trials in phase I, phase II, and phase III for treatment of AD.
resultsThere are currently 24 agents in 36 trials in phase III of AD drug development. Seven of these 24 agents are symptomatic cognitive-enhancing compounds, and 17 are disease-modifying treatments (DMTs). Most DMTs address amyloid-related targets (76%). There are 45 agents in phase II being assessed in 52 clinical trials. Phase II trials include 30 DMTs, with 26 small molecules and 4 immunotherapies. There are 24 agents in the first phase of AD drug development. DISCUSSION: Amyloid is the principal target of late-stage development programs. There are relatively few agents in clinical trials for AD suggesting a need to amplify the drug discovery ecosystem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.